Know Cancer

forgot password

Randomized PhIII Trial of Cetuximab, Bevacizumab & Biweekly Infusional 5FU/Leucovorin (FOLF-CB) vs. Oxaliplatin, Bevacizumab, & Biweekly Infusional 5FU/Leucovorin (Bev-FOLFOX) in First Line Treatment of Metastatic Colorectal Cancer

Phase 3
18 Years
Not Enrolling
Colorectal Cancer Metastatic

Thank you

Trial Information

Randomized PhIII Trial of Cetuximab, Bevacizumab & Biweekly Infusional 5FU/Leucovorin (FOLF-CB) vs. Oxaliplatin, Bevacizumab, & Biweekly Infusional 5FU/Leucovorin (Bev-FOLFOX) in First Line Treatment of Metastatic Colorectal Cancer

This is a Phase III, open label, nonblinded study. A total of 240 eligible patients will be
randomized on a 1:1 basis to either treatment Arm.

In this trial, we will compare the efficacy, safety, and tolerability of this novel
combination of biweekly infusional 5-FU/leucovorin plus cetuximab and bevacizumab (FOLF-CB)
to the current standard of care, biweekly infusional 5-FU/leucovorin plus oxaliplatin and
bevacizumab (Bev-FOLFOX). For practical purposes, this study will be a head to head
comparison of oxaliplatin versus cetuximab, since the other components of both regimens will
be the same.

Inclusion Criteria


- Histologically or cytologically confirmed colorectal cancer with metastatic disease

- Measurable disease

- Previously irradiated lesions will be considered evaluable, if they progressed since

- Has disease other than limited to surgically resectable liver-only or lung-only
metastatic disease

- Not received prior chemo and/or biotherapy for metastatic disease

- Not received oxaliplatin, bevacizumab, or cetuximab in the adjuvant setting

- May have received 5-FU, leucovorin, and/or irinotecan in the adjuvant setting,
however must have remained free of disease recurrence (including free of abnormal CEA
level) for 1- year or more

- Is >18 years of age

- ECOG performance status 0 or 1

- Normal organ & marrow function

- Use of an acceptable method of birth control

- Not pregnant or breast feeding

- Paraffin tissue block(s) or 12 (minimum) unstained slides available, for assessment
of potential predictive markers related to the EGFR, VEGF, DNA repair, and
fluoropyrimidine catabolism pathways. If no block is available, slides (typically 7
to 10 um sections, air dried on uncharged slides) may be sent

- Signed a Patient Informed Consent Form

- Signed a Patient Authorization Form (HIPAA) Form


- Had prior chemotherapy for metastatic colorectal cancer

- Received any prior treatment with oxaliplatin, bevacizumab, or cetuximab in the
adjuvant treatment of their colorectal cancer

- Currently receiving any other investigational anticancer agents or has participated
in an experimental drug study within the past 4 weeks

- History of primary CNS tumors, seizures not well-controlled with standard medical
therapy, or stroke

- Sustained hypertension, as characterized by persistent blood pressures greater than
150/100 despite medical management

- New York Heart Association (NYHA) Grade II or greater congestive heart failure or has
had angioplasty or placement of coronary stents within the past 6 months

- Clinically significant peripheral vascular disease

- History of serious allergic reactions attributed to compounds of similar chemical or
biologic composition to bevacizumab, cetuximab, oxaliplatin, fluorouracil,
leucovorin, or other agents used in the study

- Received prior cetuximab or other EGFR-directed therapy, or history of prior
anti-cancer murine or chimeric monoclonal antibody therapy; prior humanized and human
monoclonal antibody therapy is also excluded.

- Received prior treatment with bevacizumab or other agents specifically targeting VEGF
or VEGF receptors

- Uncontrolled intercurrent illness including, not limited to, ongoing or active
infection requiring parenteral antibiotics, symptomatic congestive heart failure,
uncontrolled hypertension, clinically significant cardiac arrhythmia, or psychiatric
illness/social situations that would limit compliance with study requirements in the
opinion of the Investigator/Treating Physician

- Serious or non-healing active wound ulcer, or active bone fracture

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to Day 1 of protocol treatment

- Minor surgical procedures such as fine needle aspirations or core biopsies within 7
days prior to Day 1

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to Day 1

- Current or recent use of a thrombolytic agent within last 30 days. Use for clearance
of central line catheter is permitted.

- Evidence of bleeding diathesis (disorder) or clinically significant coagulopathy
(Note that deep venous thrombosis is not regarded as a reason for exclusion from this

- Hypersensitivity to Chinese hamster ovary cell products or other recombinant human

- History of arterial thromboembolic events within 6 months

- Urine protein:creatinine ratio greater than 1.0 at screening

- Pregnant or lactating woman

- Known to be HIV positive or receiving combination anti-retroviral therapy

- Unable to comply with study requirements

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-Free Survival (PFS)

Outcome Description:

From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring). Kaplan-Meier median PFS time and PFS rate (at 12 months)

Outcome Time Frame:

(no pre-determined maximum time)

Safety Issue:


Principal Investigator

Allen Cohn, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

US Oncology Research


United States: Institutional Review Board

Study ID:




Start Date:

September 2005

Completion Date:

June 2009

Related Keywords:

  • Colorectal Cancer Metastatic
  • Colorectal Neoplasms
  • Neoplasms
  • Neoplasms, Second Primary



Memorial Sloan-Kettering Cancer Center New York, New York  10021
Texas Oncology, P.A. Dallas, Texas  75246
Virginia Oncology Associates Newport News, Virginia  23606
Comprehensive Cancer Centers of Nevada Las Vegas, Nevada  89109
Ocala Oncology Center Ocala, Florida  34474
Cancer Centers of the Carolinas Greenville, South Carolina  29605
Missouri Cancer Associates Columbia, Missouri  65201
Tyler Cancer Center Tyler, Texas  75702
Hope Center Terre Haute, Indiana  47809
Willamette Valley Cancer Center Eugene, Oregon  97401-8122
Iowa Blood and Cancer Care Cedar Rapids, Iowa  52402
Monterey Bay Oncology Monterey, California  93940
Cancer Centers of Florida, P.A. Orlando, Florida  
Rocky Mountain Cancer Center-Midtown Denver, Colorado  80218
Texas Oncology, PA Dallas, Texas  75246-2006
Utah Cancer Specialists Salt Lake City, Utah  84106
Northwest Cancer Specialists-Vancouver Vancouver, Washington  98684
Medical Oncology Associates Kingston, Pennsylvania  18704
Florida Cancer Institute New Port Richey, Florida  34652
Central Indiana Cancer Centers Indianapolis, Indiana  46227
Texas Cancer Center at Medical City Dallas, Texas  75230
Allison Cancer Center Midland, Texas  79701
West Texas Cancer Center Odessa, Texas  79761
Center for Cancer & Blood Disorders Bethesda, Maryland  20817
Hematology Oncology Associates Phoenix, Arizona  85012
Greater Dayton Cancer Center Kettering, Ohio  45409
Texas Cancer Center Abilene, Texas  79606
Texas Oncology Cancer Center Austin, Texas  78731
Mamie McFaddin Ward Cancer Center Beaumont, Texas  77702
The Texas Cancer Center Dallas, Texas  75237
San Antonio Tumor & Blood Clinic Fredericksburg, Texas  78624
Lake Vista Cancer Center Lewisville, Texas  75067
Longview Cancer Center Longview, Texas  75601
Texas Cancer Center of Mesquite Mesquite, Texas  75150
Nevada Cancer Centers Las Vegas, Nevada  89109
Raleigh Hematology Oncology Associates Cary, North Carolina  27511
Spalding Oncology Services Griffin, Georgia  30224
Cancer Center of Kansas Wichita, Kansas  67214
Minnesota Oncology Hematology, PA Minneapolis, Minnesota  55404
New York Oncology Hematology, PC Albany, New York  12208
Kalamazoo Hematology & Oncology Kalamazoo, Michigan  49048
Maryland Oncology Hematology, P.A. Columbia, Maryland  21044
Paris Regional Cancer Center Paris, Texas  75460
Waco Cancer Care and Research Center Waco, Texas  76712
Hematology Oncology Associates of Ohio & Michigan Lambertville, Michigan  48144
Hematology Oncology Associates of IL Chicago, Illinois  60611
Cancer Care & Hematology Specialists of Chicagoland Niles, Illinois  60714
Northern AZ Hematology & Oncology Assoc Sedona, Arizona  86336
Melbourne Internal Medicine Associates Melbourne, Florida  32901
El Paso Cancer Treatment Ctr El Paso, Texas  79915
South Texas Cancer Center-McAllen McAllen, Texas  78503
Texas Cancer Center-Sherman Sherman, Texas  75090
Texas Oncology Cancer Center-Sugar Land Sugar Land, Texas  77479
Cancer Care Northwest-South Spokane, Washington  99202
Yakima Valley Mem Hosp/North Star Lodge Yakima, Washington  98902
Puget Sound Cancer Center-Edmonds Edmonds, Washington  98026
Brimingham Hematology and Oncology Birmingham, Alabama  35235
Business Office - ACRC Tucson, Arizona  85715
Cancer Care Associates of Fresno Medical Group, Inc (aka California Cancer Care) Fresno, California  93720
Greeley Medical Clinic Oncology Hematology, PC Greeley, Colorado  80538
Connecticut Oncology & Hematology, LLP Torrington, Connecticut  06790
Integrated Community Oncology Network (ICON) / fka:Florida Oncology Associates Jacksonville, Florida  32204
Medical Oncology Associates of Augusta PC Augusta, Georgia  30901
Fort Wayne Medical Oncology Hematology, Inc Fort Wayne, Indiana  46815
Kansas City Cancer Centers-Southwest Overland Park, Kansas  66210
Louisiana Hematology Oncology Associates Baton Rouge, Louisiana  70809
Auerbach Hematology Oncology Associated Baltimore, Maryland  21237
Osteopathic Medical Oncology and Hematology Clinton Township, Michigan  48037
Hematology-Oncology Associates of NNJ, PA Morristown, New Jersey  07960
North Shore Hematology East Setauket, New York  11733
Northwestern Carolina Ocology Hemato Hickory, North Carolina  28602
Cancer Center Associates of Carolina, PA / fka Carolina Cancer Center Aiken, South Carolina  29801
C. Michael Jones, MD Germantown, Tennessee  38138
Texas Cancer Center-Abilene (Shouth) Abilene, Texas  79606
Texas Oncology, PA - Bedford Bedford, Texas  76022
Texas Cancer Center-Denton Denton, Texas  76210
HOAST - Medical Dr. San Antonio, Texas  78229
Puget Sound Cancer Center Seattle Seattle, Washington  98133